Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide.

Nathalie Morel 1 Anne Bachelot 2 Zeina Chakhtoura Pascale Ghillani-Dalbin 3 Zahir Amoura 4, 5 Lionel Galicier 6 Olivier Aumaitre 7 Jean-Charles Piette 4 Jacques Pourrat 8 Du Boutin Karim Sacre Jean-Emmanuel Kahn 9 Pierre Duhaut Dominique Farge 10 Camille Francès 11 Gaëlle Guettrot-Imbert Jean-Robert Harlé 12 Olivier Lambotte 13 Véronique Le Guern 14, 15 Damien Sène 4 Salim Trad Elisabeth Vidal 16, 17 Francoise Sarrot-Reynauld 18 Anne Gompel 19, 20 Marie-Laure Tanguy 21 Philippe Touraine 22, 23 Jean-Marc Lacorte Nathalie Costedoat-Chalumeau 24 Aurelien Delluc 25, 26, 27
Abstract : CONTEXT: Cyclophosphamide is used for renal and major extrarenal involvement in systemic lupus erythematosus (SLE) and is associated with a risk of premature ovarian failure. There are no data available about the relation between anti-Müllerian hormone (AMH) serum levels and the probability of subsequent pregnancy in SLE patients. OBJECTIVE: We analyzed AMH levels and the probability of pregnancy in SLE women exposed to cyclophosphamide. DESIGN AND SETTING: We conducted a matched cohort study in referral centers for SLE. PATIENTS: Fifty-six cyclophosphamide-exposed SLE women younger than 40 years of age and 56 control SLE women matched for age within 6 months participated in the study. MAIN OUTCOME MEASURES: AMH was measured in samples from the PLUS study (ClinicalTrials.gov no. NCT00413361). All patients were interviewed in May 2012 regarding their obstetric status. RESULTS: The mean age ± SD of the 112 patients was 31.6 ± 5.8 years. The mean AMH level was low (1.21 ± 1.01 ng/mL) and was significantly lower in patients exposed to cyclophosphamide (P = .03) and in patients older than 30 years (P = .02). During a median follow-up (interval between sampling and the interview) period of 4.2 (range, 2.5-4.8) years, 38 patients sought to become pregnant, and 32 (84.2%) succeeded. In the univariate analysis, the risk of failure was associated with cumulative cyclophosphamide dose (P = .007) and older age (P = .02), but not with AMH. CONCLUSION: We confirmed that AMH levels are low in SLE patients and decrease significantly with age and cyclophosphamide exposure. Nonetheless, the risk of failure to conceive was low and was predicted by cyclophosphamide exposure and age, but not by AMH levels.
Type de document :
Article dans une revue
Journal of Clinical Endocrinology and Metabolism, Endocrine Society, 2013, 98 (9), pp.3785-92. 〈10.1210/jc.2013-1235〉
Liste complète des métadonnées

http://hal.univ-brest.fr/hal-00935382
Contributeur : Ghislaine Calvez <>
Soumis le : jeudi 23 janvier 2014 - 14:30:42
Dernière modification le : mercredi 21 mars 2018 - 18:57:39

Lien texte intégral

Identifiants

Citation

Nathalie Morel, Anne Bachelot, Zeina Chakhtoura, Pascale Ghillani-Dalbin, Zahir Amoura, et al.. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide.. Journal of Clinical Endocrinology and Metabolism, Endocrine Society, 2013, 98 (9), pp.3785-92. 〈10.1210/jc.2013-1235〉. 〈hal-00935382〉

Partager

Métriques

Consultations de la notice

807